Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I–II Study
Author:
Publisher
Elsevier BV
Subject
Radiology Nuclear Medicine and imaging,Oncology
Reference47 articles.
1. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer;Kuban;Int J Radiat Oncol Biol Phys,2008
2. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy;Peeters;J Clin Oncol,2006
3. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial;Zietman;JAMA,2005
4. Fractionation and protraction for radiotherapy of prostate carcinoma;Brenner;Int J Radiat Oncol Biol Phys,1999
5. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue;Brenner;Int J Radiat Oncol Biol Phys,2002
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Photon vs proton hypofractionation in prostate cancer: A systematic review and meta-analysis;Radiotherapy and Oncology;2024-06
2. Extreme-hypofractionated RT with concomitant boost to the DIL in PCa: a 5-year update on oncological and patient-reported outcomes for the phase II trial “GIVE ME FIVE”;World Journal of Urology;2024-03-16
3. Selective sparing of bladder and rectum sub-regions in radiotherapy of prostate cancer combining knowledge-based automatic planning and multicriteria optimization;Physics and Imaging in Radiation Oncology;2023-10
4. Hypofraktionierte Strahlentherapie – ein modernisierter Klassiker;Die Onkologie;2022-06-15
5. Ten Year Results of Extensive Nodal Radiotherapy and Moderately Hypofractionated Simultaneous Integrated Boost in Unfavorable Intermediate-, High-, and Very High-Risk Prostate Cancer;Cancers;2021-10-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3